spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Recipharm and Laccure agree commercial collaboration

Recipharm Pharmaceutical Development AB

Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary

The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm’s facility in Karlskoga that specialises in the production of semi-solid products.

Over the past years, Laccure AB has successfully taken the product from innovation through clinical studies to commercial manufacturing. The development work was focused on creating a highly effective antibiotic-free product that was also user-friendly in terms of being easy to apply and not messy to use. Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure® Pessary and the exact date for the launch will be announced next year.

Laccure AB is a project company within the life science development organisation Partners for Development Investments in Life Sciences (P.U.L.S.). As it prepares for launch, the owner is endeavouring to sell the company to a buyer with the substantial resources required to bring the product to market.

Jeanette Robertsson, CEO of Laccure AB, said: “We are delighted to be collaborating with Recipharm, they are an expert partner that we can rely on for the commercial supply of our new product.

“Given the potential market for the product, a major benefit of partnering with Recipharm is that they have a high level of production capacity, which of course gives us the possibility to further scale up the batch size to meet market requirements in the future.”

It is estimated that more than 300 million women throughout the world suffer from bacterial vaginosis every year, however, there are currently no effective and safe products available that are also user-friendly and can be used with low-frequency dosages.

Laccure® Pessary is based on a patented substance that releases lactic acid, and only needs to be administered once to treat a bacterial vaginosis infection and then once a month to prevent a recurrence.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: “We are really looking forward to the commercial launch of this product, and contributing to something that will make a major difference to the lives of many women across the globe.”
web www.recipharm.com
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Avacta and Leeds University awarded £3.8m Medical Research Council funding to develop new diagnostic tests


More info >>


White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

Industry Events

PDA’s The Universe of Pre-filled Syringes and Injection Devices

7-8 November 2017, Austria Center Vienna, Bruno-Kreisky-Platz 1, 1220 Vienna, Austria

PDA celebrates the 14th Edition of The Universe of Pre-filled Syringes and Injection Devices conference this fall in Vienna, Austria, with a highly informative week with an exhibition, workshops and training courses complementing the conference’s program. Starting in November 6th through November 11th, this is the world’s largest conference on this subject.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement